New insider activity at AbCellera Biologics ( (ABCL) ) has taken place on March 8, 2025.
Director John S. Montalbano has made a significant investment in AbCellera Biologics by purchasing 60,000 shares of the company’s stock, valued at $140,400.
Recent Updates on ABCL stock
AbCellera Biologics has recently released its Q4 earnings report, highlighting its transition to a clinical-stage biotech company. Despite facing financial challenges, including a net loss of $162.9 million due to high R&D expenses and a decline in revenue to $28.8 million, the company maintains a strong liquidity position with over $800 million. Key developments include the advancement of programs ABCL635 and ABCL575 towards Phase 1 clinical trials by 2025 and a significant partnership with AbbVie focusing on the TCE platform. Stifel adjusted its price target for AbCellera, citing the company’s strategic shift from a discovery-focused partner to a fully-integrated drug development entity, reflecting reduced partnership-derived revenue and revised financing assumptions.
More about AbCellera Biologics
YTD Price Performance: -21.45%
Average Trading Volume: 3,837,880
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $712.2M
Questions or Comments about the article? Write to editor@tipranks.com